Think multi-cancer.
Build disease by disease.
Our ambition is multi-cancer early detection. We start with individual diseases so sensitivity and specificity stay central as the approach grows.
Start with one disease.
Study its biology, select complementary signals, and build a panel around the people and question it is intended to serve.
Lung cancer comes firstStudy what the whole approach adds.
Compare the panel with its individual markers. Study sensitivity and specificity across stages and populations, including independent data.
Measure the contributionConnect the disease programs.
Bring disease-specific programs into a broader system. Study the combined performance, the false-positive burden, and what happens after a signal is found.
Working toward MCEDWhat MCED means.
MCED stands for multi-cancer early detection. It describes an approach intended to look for signals associated with more than one cancer. A multi-biomarker panel is not automatically an MCED test.
The combined system, its intended population, and what happens after a signal all matter.
What broader coverage must establish.
Adding disease modules introduces questions that cannot be answered by the individual programs alone.
- Overall specificity and the burden of false-positive results.
- Sensitivity by cancer type and stage in an appropriate population.
- Tissue-of-origin performance, if that capability is part of the system.
- Follow-up pathways and evidence of clinical usefulness.
Lung first.
Then the next disease.
VarSee Lung is our first product, available for research use. The next step is to bring the same disease-specific depth to additional programs.
Our longer-term goal is to connect those programs through the MoE architecture, studying the combined system as carefully as its individual parts.